Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Moderna Inc. MRNA, -1.58% were down 2.4% in trading on Monday after the company said Switzerland exercised an option to buy an additional seven million doses of its COVID-19 booster. Moderna said delivery of those shots is set to occur in the second half of 2022.

Switzerland buys 7 million doses of Moderna's COVID-19 booster

Total of 27.5 million doses ordered by the Swiss Federal Government to date CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of Moderna's booster vaccine for delivery in the second half of 2022. These doses are in addition to the initial seven million doses of booster vaccine the Swiss Federal Government agreed to purchase for delivery in 2022 and brings Switzerland's order commitment to a total of 27.5 million doses.

Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022

AstraZeneca

Novavax

Pfizer

Could these vaccine stocks be prime additions to your portfolio today?

Good Stocks To Buy Right Now? 4 Vaccine Stocks To Check Out

Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.

Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition

Another day, another COVID-19 pill authorization.

Why Moderna Stock Is Falling Again Today

BioNTech SE

Dynavax Technologies

Intellia Therapeutics

Prothena

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

5 Biotech Stocks That More Than Doubled This Year

Moderna Inc (NASDAQ: MRNA) shares are trading lower Wednesday and are falling toward a support level. The stock was trending on social media sites throughout the day after the stock saw some movement.

Moderna Is Dipping: What's Next?

Devon Energy

Ford Motor Company

Diamondback Energy

Fortinet

Intuitive Surgical

KraneShares Global Carbon ETF

NXP Semiconductors

Atlassian

SPDR S&P Retail ETF

These 10 of the best-performing stocks of 2021 deserve to be on your watchlist. They did great in 2021 and have more room to run in 2022.

10 Stocks That Made Investors Very Happy in 2021

Marathon Digital Holdings

Upstart Holdings

This fast-paced trio at minimum tripled up the year-to-date gain of the world's largest cryptocurrency.

3 High-Growth Stocks That Crushed Bitcoin in 2021

Speaking on mRNA-1273 and its effectiveness in trials against Omicron, Dr Paul Burton said: “It's highly effective, and it's extremely safe.

Is the Moderna vaccine effective against the Omicron Variant?

The latest omicron news, plus a formal complaint from a top global charity, made some investors head for the exit.

Why Moderna Stock Slumped on Tuesday

Alibaba

General Motors

Oshkosh

Prologis

Pubmatic

Uber

The best investments going into 2022 all have strong indicators of future strength, ranging from revenue forecasts to production plans. The post 7 of the Best Investments for 2022 to Buy Now in the Stock Market appeared first on InvestorPlace.

7 of the Best Investments for 2022 to Buy Now in the Stock Market

Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.

Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron

The most-advanced vaccine developers will continue to lead the pack.

What Are the Best Vaccine Stocks to Own in 2022?

This company has been on a two-year winning streak.

Moderna Stock: Buy, Sell, or Hold in 2022?

It had much to do with a certain Greek letter.

Why Some Coronavirus Stocks Plunged Today

Virtus LifeSci Biotech Products ETF

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Johnson & Johnson

Invesco Dynamic Biotechnology & Genome ETF

ALPS Medical Breakthroughs ETF

Biotech ETFs was the biggest gainer last week.

Biotech ETFs That Outperformed Last Week

Vaccine stocks aren't enjoying a good morning today, but there's plenty of reason to suspect that they are in for a better year in 2022. The post MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

Moderna Inc. (NASDAQ:MRNA) shares gapped higher Monday morning, but have since fallen after the company announced preliminary booster data. The company's authorized booster (50 microgram dose of mRNA-1273) increases omicron neutralizing antibody levels approximately 37-fold.

What's Going On With Moderna's Stock Following Prelim Booster Data?

A third dose of Moderna's booster vaccine resulted in a 37-fold increase in antibody protection against the fast-spreading Omicron variant.

Moderna soars 9% after it says booster shot increases protection against Omicron

Moderna Inc  (NASDAQ:MRNA) is up 0.9% at at $297.34 this morning, giving back most of its pre-market surge, after the company said laboratory testing showed its Covid-19 vaccine booster appeared to be protective against the quick-spreading omicron strain.

Options Bulls Blast Moderna Stock on Booster Update

Lab tests showed that the booster shot significantly increased antibodies able to fight omicron, but with an increase in the usual side effects, the company said.

Moderna Says Its COVID-19 Booster Protects Against Omicron

Moderna Inc (NASDAQ: MRNA) has reported preliminary neutralizing antibody data against the omicron variant following its COVID-19 vaccine booster candidates at 50 µg and 100 µg dose levels.  The currently authorized 50 µg booster of mRNA-1273 increased neutralizing antibody levels against omicron approximately 37-fold compared to pre-boost levels.

Moderna's Authorized COVID-19 Booster Increases Omicron Neutralizing Antibody Levels 37-Fold

NVIDIA

And they still look like great buys heading into next year.

2 Growth Stocks That Outperformed Tesla and Bitcoin in 2021

The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 5% pre-market today. This is why it happened.

News for Moderna Stock (MRNA)